👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

Ingersoll Rand to buy ILC Dover for about $2.33 billion in life sciences push

Published 03/25/2024, 07:22 AM
Updated 03/25/2024, 11:20 AM
© Reuters.
DOV
-
IR
-

(Reuters) -Ingersoll Rand will buy ILC Dover (NYSE:DOV) from investment firm New Mountain Capital for about $2.33 billion, the air compressor maker said on Monday, bolstering its presence in the life sciences markets.

ILC, best known for being the primary supplier of spacesuits for NASA, makes products that are used for safe handling of pharmaceutical agents during drug manufacturing processes.

"Through ILC, we will get access to approximately 1,000 customers in the broader life science and healthcare sectors, where we can leverage our demand generation capabilities to drive incremental growth in other Ingersoll Rand (NYSE:IR) product lines like compressors," CEO Vicente Reynal said in a statement.

Ingersoll Rand will establish a life sciences platform within its Precision and Science Technologies segment consisting of the company's life science-focused brands plus ILC.

ILC CEO Corey Walker will lead the newly created platform and join the Ingersoll Rand leadership team. It will have about $700 million in revenue and will enable further focus in life sciences, a key strategic area for the company, Ingersoll said.

The deal, expected to close in the second quarter, includes an earnout tied to the achievement of select operating efficiency metrics in 2024.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.